Methods for determining the prognosis for patients with a prostate neoplastic condition

Abstract

The invention provide a method of identifying a biomarker that is diagnostic for survival of a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of IAPs in a neoplastic prostate cell-containing sample from patients with a prostate neoplastic condition, and (b) identifying a correlation between the level of IAPs in a sample from a patient with the survival of that patient, where the correlation of an IAP with survival in patients indicates the IAP is a biomarker diagnostic of survival of a patient with a prostate neoplastic condition. Also provided is a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a reference level of XIAP, where an increased level of XIAP in the sample correlates with increased survival of the patient. The invention further provides a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of two or more IAPs selected from the group consisting of XIAP, cIAP1, and cIAP2 in a neoplastic prostate cell-containing sample from a patient, and (b)comparing the level of the two or more IAPs in the sample to a reference level of the IAPs, where an increased level of XIAP and decreased level of cIAP1 or cIAP2 in the sample correlates with increased survival of the patient.

1 . A method of identifying a biomarker that is diagnostic for survival of a patient with a prostate neoplastic condition, comprising:
 (a) measuring the level of IAPs in a neoplastic prostate cell-containing sample from patients with a prostate neoplastic condition, and   (b) identifying a correlation between the level of IAPs in a sample from a patient with the survival of that patient,   wherein the correlation of an IAP with survival in said patients indicates said IAP is a biomarker diagnostic of survival of a patient with a prostate neoplastic condition.   
     
     
         2 . The method of  claim 1 , wherein said survival is overall survival. 
     
     
         3 . The method of  claim 1 , wherein said survival is disease-free survival. 
     
     
         4 . The method of  claim 1 , wherein said IAPs are selected from the group consisting of XIAP, cIAP1, cIAP2, and Survivin. 
     
     
         5 . The method of  claim 1 , wherein said sample is prostate tissue. 
     
     
         6 . The method of  claim 1 , wherein said sample is a fluid selected from the group consisting of blood, serum, urine, and semen. 
     
     
         7 . The method of  claim 1 , wherein said measuring comprises using an antibody specifically reactive with an IAP polypeptide. 
     
     
         8 . The method of  claim 1 , wherein a level of an IAP polypeptide is measured. 
     
     
         9 . The method of  claim 1 , wherein a level of an TAP nucleic acid is measured. 
     
     
         10 . The method of  claim 1 , wherein said patient has an early stage of prostate cancer. 
     
     
         11 . The method of  claim 1 , wherein said biomarker is used to determine if said patient is at risk for relapse. 
     
     
         12 . The method of  claim 1 , wherein said biomarker is used to determine the proper course of treatment for said patient. 
     
     
         13 - 85 . (canceled)